Dobutamine is a medication that treats heart failure by strengthening your heart muscle. Heart failure happens when your heart isn't pumping very well. A healthcare provider will give you this injection in a hospital or clinic setting. Technically, dobutamine is a synthetic catecholamine primarily acting as a beta1 adrenergic receptor agonist with modest activity at beta2 and alpha1 receptors. Intravenous infusion produces a rapid positive inotropic effect that increases stroke volume and cardiac output with generally less increase in heart rate than other catecholamines. The drug is supplied as the hydrochloride salt for parenteral use, is titratable by continuous infusion, and requires monitoring of hemodynamics, ECG, and electrolytes during administration. Standard clinical indications include short term management of cardiac decompensation due to depressed contractility, for example in cardiogenic shock or acute exacerbations of chronic heart failure where increased cardiac output is desired while awaiting definitive therapy.
Parent: Dobutamine
Parent: Dobutamine / Dobutamine Hydrochloride
Parent: Dobutamine
Parent: Dobutamine
For pharmaceutical quality control, dobutamine drug substance and injectable formulations are analyzed by validated HPLC or LC methods to quantify assay and related substances. Typical acceptance criteria used in many monographs and quality systems require assay purity at release to be high, commonly greater than or equal to 98.5 percent of label claim on a dry basis, with total related substances limited to no more than about 2.0 percent and any single unspecified impurity generally limited to about 0.5 percent. Related compounds routinely monitored include synthetic positional isomers, N-dealkylation products, demethylated analogs and oxidative products of the catechol ring such as quinone-type species; oxidative impurities and degradation products are controlled by antioxidant formulation strategies and packaging. Residual solvents and inorganic counterions are controlled to pharmacopeial limits and water content is specified for the drug substance and injection.
Dobutamine is used as a short term intravenous inotropic agent to treat acute decompensated heart failure and cardiogenic shock when increased cardiac contractility and cardiac output are required. It is administered in monitored settings to stabilize patients, improve end organ perfusion, or bridge to more definitive therapies.
Dobutamine is a synthetic catecholamine that primarily stimulates beta1 adrenergic receptors on cardiac myocytes, increasing intracellular cyclic AMP and calcium availability which enhance myocardial contractility. It has some beta2 agonist activity that can cause mild vasodilation and limited alpha1 activity that may offset extreme vasodilation, making its net vascular effects dose and context dependent.
Dobutamine is neither a pure vasopressor nor a pure vasodilator. It is classified principally as a positive inotrope. Because of beta1 mediated increases in cardiac output it can raise blood pressure in patients with low cardiac output. Concurrent beta2 activity can produce mild vasodilation, so its net effect on systemic vascular resistance varies with dose and the patient hemodynamic state.
Dobutamine tends to increase systolic blood pressure by improving stroke volume and cardiac output, particularly in patients with cardiogenic hypotension. However, because it can reduce systemic vascular resistance through beta2 mediated vasodilation in some cases, changes in mean arterial pressure can be modest and patient dependent. Continuous blood pressure monitoring and titration are required during infusion.
